ReP USP - Resultado da busca

Artigo de periodico
Circulating plasma miRNA and clinical/hemodynamic characteristics provide additional predictive information about acute pulmonary thromboembolism, chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension (2021)
Fabro, Alexandre Todorovic ; Machado-Rugolo, Juliana ; Baldavira, Camila Machado ; Prieto, Tabatha Gutierrez ; Farhat, Cecilia; Mangone, Flavia Regina Rotea; Batah, Sabrina Setembre ; Cruvinel, Heloísa Resende; Alda, Maiara Almeida; Monteiro, Jhonatas Sirino ; Padua, Adriana Inácio de; Morais, Sirlei Siani; Oliveira, Rogério Antônio de ; Santos, Marcel Koenigkam ; Martinez, José Antônio Baddini ; Setubal, João Carlos ; Rainho, Cláudia Aparecida ; Yoo, Hugo Hyung Bok ; Silva, Pedro Leme; Nagai, Maria Aparecida ; Capelozzi, Vera Luiza
Fonte: Frontiers in Pharmacology. Unidades: FMRP, IQ, FM, BIOINFORMÁTICA
Assuntos: MICRORNAS, SEQUENCIAMENTO GENÉTICO, PLASMA, HIPERTENSÃO PULMONAR, TROMBOEMBOLISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FABRO, Alexandre Todorovic et al. Circulating plasma miRNA and clinical/hemodynamic characteristics provide additional predictive information about acute pulmonary thromboembolism, chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension. Frontiers in Pharmacology, v. 12, p. 1-12 art. 648769, 2021Tradução . . Disponível em: https://doi.org/10.3389/fphar.2021.648769. Acesso em: 11 jul. 2024.
APA
Fabro, A. T., Machado-Rugolo, J., Baldavira, C. M., Prieto, T. G., Farhat, C., Mangone, F. R. R., et al. (2021). Circulating plasma miRNA and clinical/hemodynamic characteristics provide additional predictive information about acute pulmonary thromboembolism, chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension. Frontiers in Pharmacology, 12, 1-12 art. 648769. doi:10.3389/fphar.2021.648769
NLM
Fabro AT, Machado-Rugolo J, Baldavira CM, Prieto TG, Farhat C, Mangone FRR, Batah SS, Cruvinel HR, Alda M A, Monteiro JS, Padua AI de, Morais SS, Oliveira RA de, Santos MK, Martinez JAB, Setubal JC, Rainho CA, Yoo HHB, Silva PL, Nagai MA, Capelozzi VL. Circulating plasma miRNA and clinical/hemodynamic characteristics provide additional predictive information about acute pulmonary thromboembolism, chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension [Internet]. Frontiers in Pharmacology. 2021 ; 12 1-12 art. 648769.[citado 2024 jul. 11 ] Available from: https://doi.org/10.3389/fphar.2021.648769
Vancouver
Fabro AT, Machado-Rugolo J, Baldavira CM, Prieto TG, Farhat C, Mangone FRR, Batah SS, Cruvinel HR, Alda M A, Monteiro JS, Padua AI de, Morais SS, Oliveira RA de, Santos MK, Martinez JAB, Setubal JC, Rainho CA, Yoo HHB, Silva PL, Nagai MA, Capelozzi VL. Circulating plasma miRNA and clinical/hemodynamic characteristics provide additional predictive information about acute pulmonary thromboembolism, chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension [Internet]. Frontiers in Pharmacology. 2021 ; 12 1-12 art. 648769.[citado 2024 jul. 11 ] Available from: https://doi.org/10.3389/fphar.2021.648769
Artigo de periodico
Variants in epithelial-mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and predict survival in non–small cell lung cancer (2020)
Parra, Edwin Roger; Jiang, Mei; Machado-rugolo, Juliana; Yaegashi, Lygia Bertalha; Prieto, Tabatha; Farhat, Cecília; Sá, Vanessa Karen de; Nagai, Maria Aparecida ; Lima, Vladmir Cláudio Cordeiro de; Takagaki, Teresa Yae; Terra, Ricardo Mingarini ; Fabro, Alexandre Todorovic ; Capelozzi, Vera Luiza
Fonte: Archives of Pathology & Laboratory Medicine. Unidades: FM, FMRP, FSP
Assuntos: ANTÍGENOS, CARCINOMA, PULMÃO, NEOPLASIAS PULMONARES, LINFÓCITOS, IMUNOLOGIA, TAXA DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PARRA, Edwin Roger et al. Variants in epithelial-mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and predict survival in non–small cell lung cancer. Archives of Pathology & Laboratory Medicine, v. 144, n. 10, p. 1234-1244, 2020Tradução . . Disponível em: https://doi.org/10.5858/arpa.2019-0419-OA. Acesso em: 11 jul. 2024.
APA
Parra, E. R., Jiang, M., Machado-rugolo, J., Yaegashi, L. B., Prieto, T., Farhat, C., et al. (2020). Variants in epithelial-mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and predict survival in non–small cell lung cancer. Archives of Pathology & Laboratory Medicine, 144( 10), 1234-1244. doi:10.5858/arpa.2019-0419-OA
NLM
Parra ER, Jiang M, Machado-rugolo J, Yaegashi LB, Prieto T, Farhat C, Sá VK de, Nagai MA, Lima VCC de, Takagaki TY, Terra RM, Fabro AT, Capelozzi VL. Variants in epithelial-mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and predict survival in non–small cell lung cancer [Internet]. Archives of Pathology & Laboratory Medicine. 2020 ; 144( 10): 1234-1244.[citado 2024 jul. 11 ] Available from: https://doi.org/10.5858/arpa.2019-0419-OA
Vancouver
Parra ER, Jiang M, Machado-rugolo J, Yaegashi LB, Prieto T, Farhat C, Sá VK de, Nagai MA, Lima VCC de, Takagaki TY, Terra RM, Fabro AT, Capelozzi VL. Variants in epithelial-mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and predict survival in non–small cell lung cancer [Internet]. Archives of Pathology & Laboratory Medicine. 2020 ; 144( 10): 1234-1244.[citado 2024 jul. 11 ] Available from: https://doi.org/10.5858/arpa.2019-0419-OA
Artigo de periodico
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer (2019)
Machado-rugolo, Juliana; Fabro, Alexandre Todorovic ; Ascheri, Daniel; Farhat, Cecilia; Ab'saber, Alexandre Muxfeldt; Sa, Vanessa Karen de; Nagai, Maria Aparecida; Takagaki, Teresa; Terra, Ricardo; Parra, Edwin Roger; Capelozzi, Vera Luiza
Fonte: Human pathology. Unidades: FM, FMRP
Assuntos: NEOPLASIAS CEREBRAIS, METÁSTASE NEOPLÁSICA, NEOPLASIAS PULMONARES, IMUNOHISTOQUÍMICA, SEQUENCIAMENTO GENÉTICO, ONCOGENES, GENES SUPRESSORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO-RUGOLO, Juliana et al. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer. Human pathology, v. 83, p. 177-191, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.humpath.2018.08.026. Acesso em: 11 jul. 2024.
APA
Machado-rugolo, J., Fabro, A. T., Ascheri, D., Farhat, C., Ab'saber, A. M., Sa, V. K. de, et al. (2019). Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer. Human pathology, 83, 177-191. doi:10.1016/j.humpath.2018.08.026
NLM
Machado-rugolo J, Fabro AT, Ascheri D, Farhat C, Ab'saber AM, Sa VK de, Nagai MA, Takagaki T, Terra R, Parra ER, Capelozzi VL. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer [Internet]. Human pathology. 2019 ; 83 177-191.[citado 2024 jul. 11 ] Available from: https://doi.org/10.1016/j.humpath.2018.08.026
Vancouver
Machado-rugolo J, Fabro AT, Ascheri D, Farhat C, Ab'saber AM, Sa VK de, Nagai MA, Takagaki T, Terra R, Parra ER, Capelozzi VL. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer [Internet]. Human pathology. 2019 ; 83 177-191.[citado 2024 jul. 11 ] Available from: https://doi.org/10.1016/j.humpath.2018.08.026
Trabalho de evento-resumo periodico
Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients (2017)
Machado, Juliana; Nagai, Maria Aparecida; Fabro, Alexandre Todorovic; Capelozzi, Vera Luiza
Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidades: FM, FMRP
Assuntos: NEOPLASIAS PULMONARES, ADENOCARCINOMA, PULMÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Juliana et al. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 11 jul. 2024. , 2017
APA
Machado, J., Nagai, M. A., Fabro, A. T., & Capelozzi, V. L. (2017). Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
NLM
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2024 jul. 11 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Vancouver
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2024 jul. 11 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
Trabalho de evento-resumo periodico
Influence of alpha 2 do collagen V overexpression in physiophatology of fibrosis systemic sclerosis patients (2014)
Morais, J.; Martin, P.; Velosa, A. P. P.; Andrade, P. C.; Cruz, I. B.; Miracca, E. C.; Barrence, F. A. C.; Carrasco, S.; Goldeinstein-Schainberg, C.; Nagai, M. A.; Parra, E. R.; Capelozzi, V. L.; Teodoro, W. R.
Fonte: Clinical and Experimental Rheumatology. Nome do evento: Systemic Sclerosis World Congress. Unidades: FM, ICB
Assuntos: IMUNOLOGIA, EXPRESÃO GÊNICA, COLÁGENO, SISTÊMICO ESCLERODERMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MORAIS, J. et al. Influence of alpha 2 do collagen V overexpression in physiophatology of fibrosis systemic sclerosis patients. Clinical and Experimental Rheumatology. Pisa: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.clinexprheumatol.org/article.asp?a=8201. Acesso em: 11 jul. 2024. , 2014
APA
Morais, J., Martin, P., Velosa, A. P. P., Andrade, P. C., Cruz, I. B., Miracca, E. C., et al. (2014). Influence of alpha 2 do collagen V overexpression in physiophatology of fibrosis systemic sclerosis patients. Clinical and Experimental Rheumatology. Pisa: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.clinexprheumatol.org/article.asp?a=8201
NLM
Morais J, Martin P, Velosa APP, Andrade PC, Cruz IB, Miracca EC, Barrence FAC, Carrasco S, Goldeinstein-Schainberg C, Nagai MA, Parra ER, Capelozzi VL, Teodoro WR. Influence of alpha 2 do collagen V overexpression in physiophatology of fibrosis systemic sclerosis patients [Internet]. Clinical and Experimental Rheumatology. 2014 ; 32( 81): S-66-S67.[citado 2024 jul. 11 ] Available from: http://www.clinexprheumatol.org/article.asp?a=8201
Vancouver
Morais J, Martin P, Velosa APP, Andrade PC, Cruz IB, Miracca EC, Barrence FAC, Carrasco S, Goldeinstein-Schainberg C, Nagai MA, Parra ER, Capelozzi VL, Teodoro WR. Influence of alpha 2 do collagen V overexpression in physiophatology of fibrosis systemic sclerosis patients [Internet]. Clinical and Experimental Rheumatology. 2014 ; 32( 81): S-66-S67.[citado 2024 jul. 11 ] Available from: http://www.clinexprheumatol.org/article.asp?a=8201

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada